HomeProductsBioactive CompoundsApoptosisTNFElobixibat
Chemical structure of CAS 439087-18-0

Elobixibat

In Stock•Starting at $191 for 1 mg•Purity ≥ 97%
CAS No.439087-18-0
MDL No.N/A
MFC36H45N3O7S2
MW695.90
InChI KeyXFLQIRAKKLNXRQ-UUWRZZSWSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg97%$191In Stock
5 mg97%$397In Stock
10 mg97%$594In Stock
25 mg97%$1067In Stock
50 mg97%$1493In Stock
100 mg97%$1939In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.439087-18-0
Product NameElobixibat

Biological Targets

SLC10A2

Associated Conditions

Constipation·non-alcoholic steatohepatitis·Disorder of lipid metabolism
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.

Neurogastroenterology and motility • Vol. 31, Issue 5 • 2019
PMID: 30793431PMC: PMC6519041DOI: 10.1111/nmo.13571

Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.

The lancet. Gastroenterology & hepatology • Vol. 3, Issue 8 • 2018
PMID: 29805116DOI: 10.1016/S2468-1253(18)30123-7

Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.

World journal of gastroenterology • Vol. 21, Issue 24 • 2015
PMID: 26139989PMC: PMC4481438DOI: 10.3748/wjg.v21.i24.7436

Elobixibat and its potential role in chronic idiopathic constipation.

Therapeutic advances in gastroenterology • Vol. 7, Issue 4 • 2014
PMID: 25057297PMC: PMC4107709DOI: 10.1177/1756283X14528269

Documentation

Similar Products